Parkinson’s Disease

Designation enables preferred procedural treatment and review consultation by Japan’s Ministry of Health, Labor and Welfare  Parkinson’s disease affects approximately 10 million people worldwide and 250,000 in Japan  Berlin, Germany and Cambridge, MA, USA, December 17, 2025 – Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy […]

BlueRock announced that the first patient has received randomized treatment in the pivotal Phase III clinical trial, exPDite-2, of bemdaneprocel, an investigational cell therapy for Parkinson’s disease. 

Regenerative Medicine Advanced Therapy (RMAT) designation follows phase I clinical trial results demonstrating that bemdaneprocel is well tolerated with no major safety issues through 18 months  Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s […]

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months  After stopping the 12-month immune suppression regimen, assessment of 18-month data shows evidence of sustained cell engraftment […]